# A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct07070232/  
OnCo record `nct07070232` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.

## Summary

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT07070232 by BioNTech SE, with 1438 participants planned, started 2025-08-12 and due to reach its primary completion in 2028-03. Interventions recorded: BNT326, Pumitamig, Itraconazole and Paroxetine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07070232
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors
- Sponsor: BioNTech SE
- Enrolled: 1438

## Sources

- ClinicalTrials.gov NCT07070232: https://clinicaltrials.gov/study/NCT07070232

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct07070232.json